Q-omics provides the consensus-scored HS3ST6 profile across patient tissues and cancer cell-line models. HS3ST6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HS3ST6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, HS3ST6 RNA expression shows 9,858 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, KIRC, and ESCA as cancer lineages where HS3ST6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HS3ST6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HS3ST6 survival associations across molecular data types. HS3ST6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HS3ST6 RNA expression–survival associations across cancer types. High HS3ST6 expression shows unfavorable associations in UVM and ACC, but favorable associations in HNSC, CESC, LGG and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HS3ST6 RNA expression.
This table summarizes HS3ST6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HS3ST6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HS3ST6 shows lower tumor expression in KIRC, COAD, KICH, HNSC, LUAD and KIRP. The KIRC box plot shows higher HS3ST6 RNA expression in normal versus tumor tissue (log2 FC = −0.884, t-test p < 0.001).
This table shows molecular features associated with HS3ST6 in patient tissues and cancer cell lines. In patient samples, HS3ST6 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, HS3ST6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
